WO2001049282A3 - Therapeutic preparations of highly unsaturated fatty acids - Google Patents

Therapeutic preparations of highly unsaturated fatty acids Download PDF

Info

Publication number
WO2001049282A3
WO2001049282A3 PCT/US2001/000507 US0100507W WO0149282A3 WO 2001049282 A3 WO2001049282 A3 WO 2001049282A3 US 0100507 W US0100507 W US 0100507W WO 0149282 A3 WO0149282 A3 WO 0149282A3
Authority
WO
WIPO (PCT)
Prior art keywords
hufas
individual
hufa
normal
composition
Prior art date
Application number
PCT/US2001/000507
Other languages
French (fr)
Other versions
WO2001049282A2 (en
Inventor
David J Kyle
Original Assignee
Martek Biosciences Corp
David J Kyle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp, David J Kyle filed Critical Martek Biosciences Corp
Priority to AU26341/01A priority Critical patent/AU2634101A/en
Publication of WO2001049282A2 publication Critical patent/WO2001049282A2/en
Publication of WO2001049282A3 publication Critical patent/WO2001049282A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention provides a therapeutic composition comprising highly unsaturated fatty acids (HUFAs) in an amount and form sufficient to produce normal or supernormal levels of one or more of the respective HUFAs in one or more tissues of an individual in need thereof upon administration of the composition. Preferably, administration of this composition will raise the tissue level of one or more HUFA to over twice normal in a target tissue, more preferably, the tissue level of DHA is raised to over twice normal in the target tissue. Typically, the individual in need of the therapeutic composition is a mammal, especially a human, suffering from a disease selected from the group consisting of cystic fibrosis, multiple sclerosis, cerebral palsy, amyotrophic lateral sclerosis, phenylketonuria, and neurological disorders, including certain neurodegenerative diseases and psychiatric disorders. Preferably, the levels of one or more of the respective HUFAs, especially DHA, are normalized or supernormalized in membranes of the individual. In another preferred mode of this invention, the HUFAs in the therapeutic composition are in a readily absorbable form, such that the dose of HUFA required to achieve normal or supernormal levels in the individual is lower than the dose required for HUFA-containing triglycerides. For example, the HUFAs may be predominantely in the form of glycerol esters. Preferably at least 70% of the HUFAs are esterified to glycerol; more preferably, the HUFAs are predominantely in the form of diglycerides and/or monoglycerides.
PCT/US2001/000507 2000-01-06 2001-01-08 Therapeutic preparations of highly unsaturated fatty acids WO2001049282A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU26341/01A AU2634101A (en) 2000-01-06 2001-01-08 Therapeutic preparations of highly unsaturated fatty acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17470800P 2000-01-06 2000-01-06
US60/174,708 2000-01-06

Publications (2)

Publication Number Publication Date
WO2001049282A2 WO2001049282A2 (en) 2001-07-12
WO2001049282A3 true WO2001049282A3 (en) 2002-04-04

Family

ID=22637185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000507 WO2001049282A2 (en) 2000-01-06 2001-01-08 Therapeutic preparations of highly unsaturated fatty acids

Country Status (2)

Country Link
AU (1) AU2634101A (en)
WO (1) WO2001049282A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9916537D0 (en) 1999-07-14 1999-09-15 Univ Hull Culture of microorganisms for the synthesis of a polyunsaturated fatty acid
GB2377455A (en) 2001-02-09 2003-01-15 Univ Hull Method of culturing crypthecodinium cohnii
EP1531687A4 (en) 2002-06-18 2006-11-15 Martek Biosciences Corp Stable emulsions of oils in aqueous solutions and methods for producing same
US20090215896A1 (en) * 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
WO2010028419A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
ITMI20101666A1 (en) * 2010-09-13 2012-03-14 Dmf Dietetic Metabolic Food S R L COMPOSITION BASED ON DOCOSAESAENOIC ACID (DHA), IN THE TREATMENT OF CYSTIC FIBROSIS AND NON-ALCOHOLIC HEPATIC STEATOSIS
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US20150004224A1 (en) 2012-01-06 2015-01-01 Omthera Phrmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
JP6173437B2 (en) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド Statins and omega-3 fatty acid compositions
CN115141859A (en) 2013-12-20 2022-10-04 玛拉可再生能源公司 Method for recovering oil from microorganisms
MA41120A (en) * 2014-12-02 2017-10-10 Afimmune Ltd COMPOSITIONS INCLUDING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING THEM

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075231A (en) * 1986-09-17 1991-12-24 Jouveinal S.A. Lipases and lipase extracts, their preparation process and their therapeutic use
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075231A (en) * 1986-09-17 1991-12-24 Jouveinal S.A. Lipases and lipase extracts, their preparation process and their therapeutic use
WO1996040106A2 (en) * 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARLIER H ET AL: "DIGESTION AND ABSORPTION OF POLYUNSATURATED FATTY ACIDS", REPRODUCTION NUTRITION DEVELOPMENT, vol. 31, no. 5, 1991, pages 475 - 500, XP001037253, ISSN: 0926-5287 *
YUKIHISA TANAKA ET AL: "CONCENTRATION OF DOCOSAHEXAENOIC ACID IN GLYCERIDE BY HYDROLYSIS OF FISH OIL WITH CANDIDA CYLINDRACEA LIPASE", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, AMERICAN OIL CHEMISTS' SOCIETY. CHAMPAIGN, US, vol. 69, no. 12, 1 December 1992 (1992-12-01), pages 1210 - 1214, XP000330808, ISSN: 0003-021X *
ZU-YI LI ET AL: "LIPASE-CATALYZED ESTERIFICATION OF GLYCEROL AND N-3 POLYUNSATURATED FATTY ACID CONCENTRATE IN ORGANIC SOLVENT", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, AMERICAN OIL CHEMISTS' SOCIETY. CHAMPAIGN, US, vol. 70, no. 8, 1 August 1993 (1993-08-01), pages 745 - 748, XP000387538, ISSN: 0003-021X *

Also Published As

Publication number Publication date
WO2001049282A2 (en) 2001-07-12
AU2634101A (en) 2001-07-16

Similar Documents

Publication Publication Date Title
WO2001049282A3 (en) Therapeutic preparations of highly unsaturated fatty acids
RU94000061A (en) Cholesterol esters and unsaturated fatty acids, the method of treatment and the pharmaceutical or cosmetic composition
EP2258447A3 (en) Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
AP2000001943A0 (en) Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent.
DE69232564T2 (en) PHOSPHOLIPIDS
CL2010000383A1 (en) Esters and amide of carboxylic acids containing a non-steroidal anti-inflammatory agent; pharmaceutical composition: and its use as 5-lipoxygenase inhibitors to prevent or relieve tissue edema, inflammation and congestion of the conjunctiva, corneal clouding and damage to ophthalmic tissues (divisional sol. 3109-99).
CA2382262A1 (en) A nutritional supplement for lowering serum triglyceride and cholesterol levels
EP1315831B8 (en) Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
NZ515911A (en) Implantable gel compositions and method of manufacture
CA2289717A1 (en) Novel therapy for constipation
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
WO1999017742A3 (en) Taste masked formulations
ATE279209T1 (en) INJECTABLE PHARMACEUTICAL COMPOSITION FOR SYSTEMIC ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE INGREDIENTS CONTAINING MEDIUM CHAIN TRIGLYCERIDES
RU2002107450A (en) Solid Lipid Compositions
NZ250583A (en) Pharmaceutical, nutritional, or skin care compositions containing an ester of a cholesterol and fatty acid
WO1999033355A3 (en) Fat blend
CA2534202A1 (en) Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination
HUP0204513A3 (en) Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
EP1886679A3 (en) Methods for controlling highly unsaturated fatty acid content in various tissues
EP0451654A3 (en) Use of n-alkylated 1,4-dihydropyridine carboxylic acid esters as drugs, new compounds and process for their preparation
WO2000004887A3 (en) Compositions comprising phytosterol, phytostanol or mixtures of both and omega-3 fatty acids or derivatives thereof and use of the composition in treating or preventing cardiovascular disease and other disorders
JP2001525370A (en) Use of a phospholipid complex of Vitis Vinifera extract as an anti-atherosclerotic agent
CA2201855A1 (en) Preventive or remedy for diseases caused by abnormalities in cartilage tissues
AU4474893A (en) Fatty acid treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP